

Dear Christopher Feinmann,

On reading through your report, I feel that Merck Serona need to do further research to prove their case.

I do consider that all the relevant evidence has been taken into account.

The summaries of clinical and cost effectiveness leaves my head swimming and as a patient cost is irrelevant if the drug is successful.

I consider that the provisional recommendations of the Appraisal Committee are sound and provide a suitable base for the preparation of guidance to the NHS.

I feel the need for special consideration be given to the use of Cetuximab for the patients who are slowly dying of head and neck cancer. These patients die long and lingering deaths as the tumours fill their mouths obstructing airways / eating and speaking. If the drug combined with radiotherapy can shrink these tumours then this will provide a more dignified route to death. helping not only the patient but their families and loved ones also the professionals who care for them.

██████████ - Let's Face It

---

Delivered via MessageLabs

---